| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6259296c407994ff41dbb6a3b672c998 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70571
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70578
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70517 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-725
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705 |
| filingDate |
2021-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b9d8a4a263e224cb95e76d11fcb2e5d4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a2de5eed0e8754f791cc2a87fd76a609
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_88559021780ad4d152ca93e58dfbc708
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e524f98a6508b05341e70c368c75e798 |
| publicationDate |
2022-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2022136503-A1 |
| titleOfInvention |
Chimeric autoantibody receptor (caar) comprising a nicotinic acetylcholine receptor autoantigen |
| abstract |
The invention relates to a chimeric autoantibody receptor (CAAR) and nucleic acid molecules encoding said CAAR, wherein the CAAR comprises an extracellular domain comprising an autoantigen of a nicotinic acetylcholine receptor (nAChR) or fragment thereof. The invention relates further to a vector comprising a nucleic acid molecule encoding the CAAR, to a CAAR polypeptide, to a genetically modified cell expressing the CAAR or comprising a nucleic acid molecule or a vector encoding the CAAR. The invention relates further to genetically modified cells expressing the CAAR for use in the treatment of a neuromuscular disorder associated with autoantibodies that bind a nicotinic acetylcholine receptor (nAChR), preferably for the treatment of myasthenia gravis (MG). |
| priorityDate |
2020-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |